Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Change in Accured Expenses (2019 - 2025)

Historic Change in Accured Expenses for Harmony Biosciences Holdings (HRMY) over the last 7 years, with Q3 2025 value amounting to $28.0 million.

  • Harmony Biosciences Holdings' Change in Accured Expenses rose 1524.32% to $28.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.1 million, marking a year-over-year decrease of 624.52%. This contributed to the annual value of $11.8 million for FY2024, which is 7461.38% down from last year.
  • Per Harmony Biosciences Holdings' latest filing, its Change in Accured Expenses stood at $28.0 million for Q3 2025, which was up 1524.32% from -$7.0 million recorded in Q2 2025.
  • In the past 5 years, Harmony Biosciences Holdings' Change in Accured Expenses registered a high of $37.8 million during Q3 2022, and its lowest value of -$22.8 million during Q4 2022.
  • Its 5-year average for Change in Accured Expenses is $5.9 million, with a median of $5.8 million in 2021.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first skyrocketed by 53586.46% in 2022, then tumbled by 63747.61% in 2024.
  • Over the past 5 years, Harmony Biosciences Holdings' Change in Accured Expenses (Quarter) stood at $8.7 million in 2021, then plummeted by 360.98% to -$22.8 million in 2022, then soared by 235.23% to $30.8 million in 2023, then plummeted by 59.13% to $12.6 million in 2024, then surged by 122.87% to $28.0 million in 2025.
  • Its Change in Accured Expenses was $28.0 million in Q3 2025, compared to -$7.0 million in Q2 2025 and -$5.5 million in Q1 2025.